SK Biopharmaceuticals agreed to acquire Biohaven’s Kv7.2/7.3 potassium channel activator opakalim (BHV-7000) in a $795 million deal, positioning the asset as a potential follow-on epilepsy franchise product. Biohaven will receive $400 million at closing and $50 million due in 2027, with the asset in Phase II/III for focal epilepsy. SK argued that it can accelerate commercialization by leveraging an established epilepsy field force, payer access infrastructure, and patient support programs built around its existing XCOPRI franchise. The transaction is subject to customary conditions, including U.S. Hart-Scott-Rodino clearance, and is expected to close following regulatory reviews.